Biological features of biofilm-forming ability of Acinetobacter baumannii strains derived from 121 elderly patients with hospital-acquired pneumonia

Clinical and Experimental Medicine

Volumn 16, Issue 1, 2016, Pages 73-80

  Zhang, Duchao ^a   Xia, Jingjing ^a,b   Xu, Yaping ^a   Gong, Meiliang ^a   Zhou, Yu ^a   Xie, Lixin ^a   Fang, Xiangqun ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acinetobacter baumannii; Adhesion ability; Antibiotic susceptibility; Biofilm forming ability

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFOPERAZONE; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CIPROFLOXACIN; CRYSTAL VIOLET; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULFAMETHOXAZOLE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTERIUM ISOLATION; BIOFILM; BIOFILM FORMING ABILITY; BIOLOGICAL ACTIVITY; CLINICAL FEATURE; CONTROLLED STUDY; GERIATRIC DISORDER; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HUMAN CELL; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY; AGED; BACTERIUM ADHERENCE; CELL LINE; CROSS INFECTION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; PNEUMONIA; SPUTUM; VERY ELDERLY;

ACINETOBACTER BAUMANNII; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BIOFILMS; CELL LINE; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; SPUTUM;

EID: 84957937429     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-014-0333-2     Document Type: Article

References (26)

1. Karakoc C, Tekin R, Yeşilbağ Z, Cagatay A. Risk factors for mortality in patients with nosocomial Gram-negative rod bacteremia. Eur Rev Med Pharmacol Sci. 2013;17:951–7.
2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5:939–51.
3. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:3471–84.
4. Montefour K, Frieden J, Hurst S, et al. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse. 2008;28:15–25.
5. Alsan M, Klompas M. Acinetobacter baumannii: an emerging and important pathogen. JCOM. 2010;17:363–9.
6. Sebeny PJ, Riddle MS, Petersen K. Acinetobacter baumannii skin and soft-tissue infection associated with war trauma. Clin Infect Dis. 2008;47:444–9.
7. Chen BY, He LX, Hu BJ. Expert consensus for the diagnosis, therapy and prevention of Acinetobacter baumannii infection in China. Chin Med J. 2012;92:76–82.
8. American Thoracic Society-Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
9. Longo F, Vuotto C, Donelli G. Biofilm formation in Acinetobacter baumannii. New Microbiol. 2014;37:119–27.
10. Lee HW, Koh YM, Kim J, et al. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect. 2008;14:49–54.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement[S]. 2007;29: M100-16.
12. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–93.
13. Beck-Sague CM, Jarvis WR, Brook JH, et al. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units. Am J Epidemiol. 1990;132:723–33.
14. Hirai Y. Survival of bacteria under dry conditions; from a viewpoint of nosocomial infection. J Hosp Infect. 1991;19:191–200.
15. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95–108.
16. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–22.
17. Beachey EH, Giampapa CS, Abraham SN. Bacterial adherence. Adhesin receptor-mediated attachment of pathogenic bacteria to mucosal surfaces. Am Rev Respir Dis. 1988;138:S45–8.
18. Lee JC, Koerten H, van den Broek P, et al. Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol. 2006;157:360–6.
19. Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperoneeusher pili assembly system. Microbiology. 2003;149:3473–84.
20. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect. 2004;10:684–704.
21. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother. 2001;45:3375–80.
22. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother. 2003;52:629–35.
23. Klemm P, Schembri MA. Bacterial adhesins: function and structure. Int J Med Microbiol. 2000;290:27–35.
24. Gaddy JA, Actis LA. Regulation of Acinetobacter baumannii biofilm formation. Future Microbiol. 2009;4:273–8.
25. Joung MK, Kwon KT, Kang CI, et al. Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii. J Infect. 2010;61:212–8.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.